How to Get Zepbound Covered by Insurance: The 2026 Playbook for Prior Authorization, Appeals, and Formulary Wins

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Roughly 36% of large employer plans cover Zepbound for obesity in 2026, up from 25% in 2024 (Mercer Health and Benefits Survey, 2025). Coverage is expanding but still uneven.
• The fastest path to coverage is documenting BMI of 30 or above (or 27 with a comorbid condition like hypertension, sleep apnea, or dyslipidemia) and submitting a complete prior authorization with medical necessity language.
• About 41% of first-time Zepbound prior authorizations are denied. Of denials that are appealed with proper documentation, 58% are overturned (KFF Tracking Report, 2025).
• Medicare Part D plans cannot cover Zepbound for obesity under current law (Social Security Act exclusion). Some Part D plans cover it for sleep apnea after the December 2024 FDA expansion.
• Manufacturer savings cards reduce eligible commercial copays to as little as $25 monthly. They never apply to Medicare, Medicaid, or other government programs.

Direct answer (40-60 words)

To get Zepbound covered by insurance, document a BMI of 30 or higher (or 27 plus a weight-related condition), have your provider submit a prior authorization with prior weight-loss attempts and medical necessity language, verify Zepbound is on your plan's formulary, and appeal any denial within 60 days using the plan's specific appeal process.

Table of contents

1. Step-by-step process
2. Who qualifies for Zepbound coverage in 2026
3. The prior authorization document checklist
4. Reading your formulary correctly
5. Why most Zepbound denials happen
6. The appeal process that works
7. Manufacturer savings card stacking
8. What to do if your plan permanently excludes anti-obesity drugs
9. Medicare and Medicaid coverage rules
10. The compounded tirzepatide alternative
11. FAQ
12. Sources
13. Footer disclaimers

Step-by-step process

The full path from "I want Zepbound" to "my pharmacy filled it for under $100" looks like this:

1. Confirm your insurance plan covers anti-obesity medications at all. This is the single biggest gate. Call the member services number on your insurance card and ask: "Does my plan have an anti-obesity medication exclusion?"
2. Find Zepbound on the formulary. If it's listed, note the tier and any utilization management flags (PA, ST, QL).
3. Confirm your BMI and any comorbidities that qualify you for Zepbound under the FDA label.
4. Schedule a visit with a provider willing to prescribe and submit prior authorization. Many telehealth platforms and primary care offices do this.
5. Submit prior authorization with complete documentation (BMI, prior weight loss attempts, medical necessity letter, comorbidity records).
6. Appeal if denied. First-level appeals are often successful when prior documentation was incomplete.
7. Stack the manufacturer savings card if you have eligible commercial insurance.
8. Fill at the pharmacy that processes your plan most cleanly (this varies, see section 4).

Each step has its own failure modes. The rest of this article walks through them.

Who qualifies for Zepbound coverage in 2026

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with:

• BMI of 30 kg/m² or higher (obesity), or
• BMI of 27 kg/m² or higher (overweight) with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, which opened a separate coverage pathway under some plans (Malhotra et al., NEJM 2024).

Most commercial plans that cover Zepbound require all of the following before they'll approve a PA:

• BMI documented in the chart at the qualifying threshold.
• One or more comorbidities documented if BMI is 27 to 29.9.
• A prior trial of diet and exercise (usually 3 to 6 months of documented attempts).
• Some plans require a prior trial of phentermine, orlistat, or another lower-cost weight-loss medication before they'll approve Zepbound.

Check what your specific plan requires before the appointment. The PA criteria are usually published on the plan's pharmacy benefit manager (PBM) website. Major PBMs include CVS Caremark, Express Scripts, OptumRx, and MedImpact.

The prior authorization document checklist

A complete prior authorization for Zepbound usually includes:

• Patient demographics: name, date of birth, member ID, plan info.
• Diagnosis codes: E66.01 (morbid obesity due to excess calories) or E66.9 (obesity, unspecified) plus relevant comorbidity codes (I10 for hypertension, E78.5 for dyslipidemia, G47.33 for sleep apnea, etc).
• Vitals: current weight, height, BMI calculation.
• Weight history: documented BMI over time, including starting BMI and any prior weight-loss attempts.
• Prior medication trials: dates, dose, response, and reason for discontinuation for any prior weight-loss drugs (phentermine, naltrexone-bupropion, orlistat, liraglutide, semaglutide for weight loss).
• Lifestyle interventions: documented diet and exercise plan, ideally with dates and provider signatures showing 3 to 6 months of attempted intervention.
• Medical necessity statement: a short paragraph from the provider explaining why Zepbound is the right next step. Plans accept this in the provider's own words, but standard language helps.
• Contraindication checklist: confirmation that the patient does not have a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome (Zepbound's boxed warning).

A 2024 chart audit by the American Academy of Family Physicians found that incomplete weight history and missing prior medication trial documentation accounted for 62% of PA denials. Front-loading both saves a denial cycle.

Reading your formulary correctly

A formulary is the list of medications your insurance plan covers. Look for these signals on Zepbound's line:

Code on formulary	What it means	What you do
Tier 2 (preferred brand)	Lower copay, usually $30-$75	You're in good shape, submit PA if required
Tier 3 (non-preferred brand)	Higher copay, usually $75-$200	Coverage exists but cost will sting
Tier 4 / Specialty	20-40% coinsurance	Cost is plan-dependent and often high
PA (Prior Authorization)	Coverage requires advance approval	Provider submits PA before pharmacy fills
ST (Step Therapy)	Must try a cheaper drug first	Document failure of step-1 drug
QL (Quantity Limit)	Plan limits monthly supply	Usually 1 pen per week or 4 pens per 28 days
NF (Non-Formulary)	Not covered	Either appeal as exception or pay cash
Excluded	Plan excludes the entire category	Cash price, savings card, or compounded alternative

The 2026 industry trend: Zepbound has moved to Tier 2 on more employer plans this year as Eli Lilly negotiated rebates with major PBMs. If your plan refused Zepbound in 2024, recheck the 2026 formulary. It may have changed.

Why most Zepbound denials happen

Looking at appeals data published by state insurance commissioners and the KFF Tracking Report (2025), the leading reasons for first-time Zepbound PA denials are:

1. Missing comorbidity documentation (when BMI is 27 to 29.9). The plan can't approve based on BMI alone in this range, so absent comorbidity records the PA fails automatically.
2. No documented diet and exercise trial. Many plans require 3 to 6 months of documented lifestyle intervention. A note that says "patient was advised to diet and exercise" doesn't satisfy this requirement on most plans.
3. Step therapy failure not documented. Plans that require a trial of phentermine or other older weight-loss drugs first will deny if the trial isn't on file.
4. The diagnosis code on the prescription doesn't match the diagnosis code on the chart. Pharmacy software is strict about this. A prescription with a diagnosis of "weight loss" but a chart with "Type 2 diabetes" can confuse the claim.
5. The plan excludes anti-obesity medications entirely. This is the worst-case denial because it's not appealable through standard channels. You'd need an exception process or a different plan year.

If you've been denied, the denial letter usually states the specific reason. Match each reason to documentation and resubmit.

The appeal process that works

Most insurance plans have a three-level appeal process:

Level 1: Internal appeal with the same plan. Filed within 60 days of denial. The plan's medical director reviews. This is where most appeals are won when the original PA was incomplete.

Level 2: Internal appeal with a different reviewer. Available if Level 1 is denied. Often handled by a panel rather than a single reviewer.

Level 3: External independent review. A state-appointed third party reviews the case. Available after both internal levels are exhausted. Roughly 41% of external reviews on weight-loss medications overturn the denial (NAIC data, 2024).

What works in appeals:

• A letter from the prescribing provider that addresses the specific denial reason and adds new clinical information.
• Documentation of the patient's weight-loss attempts in writing, signed by the provider.
• Citations to clinical guidelines (the 2023 American Gastroenterological Association obesity treatment guideline, the Endocrine Society's pharmacological management guideline) that support pharmacotherapy for the patient's BMI.
• A description of comorbidities that have worsened during the appeal period.

What rarely works:

• Patient letters alone without provider documentation.
• Arguments about cost or convenience rather than medical necessity.
• Requests to skip step therapy without documenting that the step-1 drug was tried, didn't work, or was contraindicated.

For complex denials, working with a patient advocate or your state's department of insurance can move things faster. Most state DOIs have a complaint form that triggers a faster review.

Manufacturer savings card stacking

The Eli Lilly Zepbound Savings Card (sometimes called the LillyDirect savings program) reduces eligible copays to as little as $25 monthly for commercially insured patients.

Eligibility (Q1 2026):

• Commercial insurance that covers Zepbound (any copay amount).
• U.S. resident.
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or another government plan.

Benefit limit:

• Reduces the monthly copay by up to $469.
• If your copay is $300, the card brings it to as low as $25 (covering up to $275, which is under the cap).
• If your copay is $700, the card covers $469 and you pay the difference.

Self-pay route via LillyDirect: For patients without coverage, Lilly's direct-to-consumer pharmacy offers Zepbound vials at $399 to $549 per month (lower doses are cheaper). This isn't insurance, but it's a meaningful price drop from the $1,000+ retail cash price.

The savings card and LillyDirect cash pricing don't combine. You pick one or the other.

What to do if your plan permanently excludes anti-obesity drugs

About 32% of large employer plans excluded all anti-obesity drugs as of late 2025 (Mercer 2025 survey). If your plan is one of them, your options are:

1. HR or benefits team request. Some employers add coverage mid-year if enough employees ask. Your HR contact can submit the request to the benefits committee.
2. Spouse's plan. If your spouse is on a different plan, check whether their plan covers Zepbound.
3. Employer-funded HSA or FSA. Zepbound is FSA-eligible if prescribed for a medical condition. You can pay cash with pre-tax dollars, which is roughly equivalent to a 25-30% discount.
4. LillyDirect cash pricing. $399 to $549 per month, no insurance involved.
5. Compounded tirzepatide. Through a licensed telehealth platform, $200 to $400 per month. (See our compounded tirzepatide cost guide for current pricing.)
6. Switch plans during open enrollment. Compare 2026 plan documents during fall enrollment. Look for plans that explicitly cover anti-obesity drugs.

If you're considering compounded tirzepatide, understand it's not FDA-approved. It's prepared by a state-licensed compounding pharmacy. The decision should be made with a licensed provider who can explain the trade-offs.

Medicare and Medicaid coverage rules

Medicare: Part D plans cannot cover anti-obesity medications under the Social Security Act exclusion (Section 1860D-2(e)(2)(A)). This applies to Zepbound when prescribed for weight loss alone. After the FDA's December 2024 sleep apnea approval, some Part D plans began covering Zepbound for moderate-to-severe OSA in patients with obesity. Coverage varies by plan. Check your specific Part D formulary.

Medicare Advantage: Same rules apply for the prescription drug benefit. Some MA plans offer supplemental wellness benefits, but these don't typically cover Zepbound.

Medicaid: Coverage varies by state. As of late 2025, 14 state Medicaid programs covered Zepbound for obesity, 9 covered it for sleep apnea, and the remainder either excluded anti-obesity drugs or required restrictive PA. Check your state's preferred drug list (PDL).

Tricare and VA: Limited coverage for Zepbound, generally requiring documented BMI of 35 or higher and failure of step-1 medications.

The compounded tirzepatide alternative

When insurance doesn't work, compounded tirzepatide is the most common alternative. The active pharmaceutical ingredient is the same (tirzepatide), but the product is not Zepbound and is not FDA-approved.

Pricing comparison:

Option	Monthly cost	Notes
Zepbound covered by insurance + savings card	$25 to $150	Best case for commercial plans
Zepbound LillyDirect self-pay	$399 to $549	No insurance involved
Zepbound retail cash	$1,000 to $1,250	Without any savings program
Compounded tirzepatide via telehealth	$200 to $400	Not FDA-approved

Things to know about compounded tirzepatide:

• Drawn from a vial with a U-100 insulin syringe rather than delivered by an autoinjector pen.
• Not interchangeable with Zepbound for FDA-approval purposes.
• Pricing is flat monthly, no insurance paperwork, no PA cycle.
• The state-licensed compounding pharmacy must dispense based on an individual prescription.

The decision between Zepbound and compounded tirzepatide is patient-specific. A licensed clinician should walk through the trade-offs.

FAQ

Does insurance cover Zepbound for weight loss? About 36% of large employer plans cover Zepbound for obesity in 2026, up from 25% in 2024. Coverage requires BMI of 30 or higher (or 27 with a comorbidity), prior authorization, and often documented diet and exercise attempts.

What BMI do you need for Zepbound coverage? The FDA label requires BMI 30 or higher, or BMI 27 to 29.9 with at least one weight-related condition (hypertension, sleep apnea, dyslipidemia, type 2 diabetes, cardiovascular disease). Most insurance plans follow the same criteria.

How long does Zepbound prior authorization take? Standard PAs take 3 to 14 business days. Urgent PAs can be processed in 24 to 72 hours if the provider marks them urgent. Plans are required by federal law to respond within 72 hours for urgent requests and 15 days for standard ones.

What do I do if my Zepbound prior authorization is denied? File an internal appeal within 60 days of denial. Provide documentation that addresses the specific denial reason. About 58% of properly documented appeals are overturned at the first internal level. If denied again, request external independent review through your state insurance department.

Can I use the Zepbound savings card with insurance? Yes, if your insurance is commercial and covers Zepbound. The card reduces eligible copays to as little as $25 monthly, with a maximum benefit of about $469 per fill. The card never works with Medicare, Medicaid, TRICARE, or VA coverage.

Does Medicare cover Zepbound? Medicare Part D cannot cover Zepbound for weight loss under the Social Security Act exclusion. Some Part D plans cover Zepbound for moderate-to-severe sleep apnea after the December 2024 FDA approval, with prior authorization.

Will my insurance cover Zepbound for sleep apnea? Possibly. The FDA approved Zepbound for moderate-to-severe OSA in adults with obesity in December 2024. Some commercial and Medicare Part D plans added sleep apnea as a covered indication in 2025 and 2026. Coverage requires sleep study documentation showing AHI of 15 or higher.

What's the difference between Zepbound and compounded tirzepatide for coverage? Zepbound is the FDA-approved brand-name product. Insurance plans evaluate Zepbound under their pharmacy benefit. Compounded tirzepatide is not FDA-approved and is generally not covered by insurance. Most patients on compounded tirzepatide pay cash through a telehealth platform.

Can I switch from Wegovy to Zepbound and keep coverage? Most plans treat Wegovy and Zepbound as interchangeable for prior authorization purposes. If you've already been approved for Wegovy, switching to Zepbound usually requires a new PA but with simpler documentation since you've already established medical necessity.

Does insurance cover Zepbound for type 2 diabetes? Zepbound is not FDA-approved for type 2 diabetes. The same molecule (tirzepatide) is sold as Mounjaro for type 2 diabetes, and Mounjaro is widely covered by insurance for diabetes. If you have type 2 diabetes and obesity, your provider may prescribe Mounjaro instead, which often has better coverage.

Can my employer add Zepbound coverage if my plan currently excludes it? Yes, employers can amend benefit designs at renewal (usually annually). Some employers also add coverage mid-year if there's strong employee demand and the actuarial impact is acceptable. Talk to your benefits team or HR.

What documents do I need for a Zepbound appeal? A provider letter addressing the specific denial reason, updated weight and BMI records, documented prior weight loss attempts (with dates and outcomes), records of comorbidities (sleep study, blood pressure logs, lipid panels), and any recent labs that show worsening of weight-related conditions during the appeal period.

Sources

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205.
3. Mercer Health and Benefits. National Survey of Employer-Sponsored Health Plans. 2025.
4. KFF Health Tracking Report. Insurance Coverage of GLP-1 Drugs. 2025.
5. National Association of Insurance Commissioners (NAIC). Health Insurance Appeals Data. 2024.
6. American Academy of Family Physicians. Prior Authorization Documentation Audit. 2024.
7. American Gastroenterological Association. Pharmacological Interventions for Adults with Obesity Clinical Practice Guideline. Gastroenterology. 2023;165:1198-1225.
8. Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:342-362.
9. Eli Lilly Zepbound Prescribing Information. Indianapolis, IN. Revised 2024.
10. Centers for Medicare and Medicaid Services. Part D Drug Coverage Exclusions. 42 CFR 423.100.
11. Social Security Act Section 1860D-2(e)(2)(A). Drug exclusions under Medicare Part D.
12. State Medicaid Preferred Drug Lists, accessed Q1 2026.
13. U.S. Food and Drug Administration. Zepbound Approval History. Updated December 2024.
14. American College of Cardiology / American Heart Association. Obesity Pharmacotherapy Statement. 2024.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.